Niagen Bioscience fell 71.0% from $6.93 to $2.01, behind the S&P 500's +11.2%. Its worst day was Nov 5 (−16.5%), and its low came Nov 16 at $2.01.
Story events cover the past 12 months · Times ET
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Niagen Bioscience closed at its highest level of the year, 1.6% above where the year started.
+2.6% · S&P 500 +0.9%
EPS of $0.03 beat the $0.01 estimate on $33.8M revenue (est. $31.5M); FY revenue guidance of $139.0M–$145.3M against the $153.3M consensus.
+3.2% · S&P 500 −0.6%
EPS of $0.07 beat the $0.06 estimate on $31.5M revenue (est. $30.7M); FY revenue guidance of $139.0M–$145.3M against the $145.9M consensus.
−15.7% · S&P 500 −0.3%
EPS of $0.01 missed the $0.02 estimate on $29.8M revenue (est. $31.4M); FY revenue guidance of $139.0M–$145.3M against the $142.3M consensus.
−14.7% · S&P 500 −0.2%
Niagen Bioscience shares fell 8.2%, while the S&P 500 rose 0.2%.
−8.2% · S&P 500 +0.2%
EPS of $-0.01 beat the $-0.03 estimate on $27.2M revenue (est. $32.9M); FY revenue guidance of $145.3M–$151.6M against the $130.7M consensus.
−16.5%, the year's worst day · S&P 500 −4.4%
Where it ended: a close of $2.01 on Nov 16, 2026. Up next: Q4 2026 earnings on Mar 3, 2027 (EPS est. $-0.05, revenue est. $30.0M).
Nothing in the past 12 months.
All NAGE dividend history